Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 1,000 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,000 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $20.00, for a total value of $20,000.00. Following the sale, the insider owned 51,776 shares in the company, valued at approximately $1,035,520. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $26,100.00.

Avalo Therapeutics Stock Down 2.6%

AVTX stock opened at $19.01 on Thursday. The firm has a market capitalization of $1.01 billion, a PE ratio of -3.48 and a beta of 0.78. Avalo Therapeutics, Inc. has a twelve month low of $6.51 and a twelve month high of $24.27. The stock has a 50-day simple moving average of $16.93 and a two-hundred day simple moving average of $16.17.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, equities research analysts anticipate that Avalo Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG grew its stake in Avalo Therapeutics by 956.9% in the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after buying an additional 432,608 shares in the last quarter. Moody Aldrich Partners LLC purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $2,419,000. Nan Fung Trinity HK Ltd. purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $3,432,000. Jennison Associates LLC bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth $8,637,000. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the last quarter. 87.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Friday, July 24th. Wedbush cut their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Citizens Jmp decreased their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Leerink Partners began coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective on the stock. Finally, Weiss Ratings lowered Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.80.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.